Stalevo, a drug used to treat Parkinson’s disease, is undergoing as a safety review because of concerns that it could put patients at a higher risk of cardiac problems than another drug called Sinemet.
It’s important to note that the US Food & Drug Administration (FDA) has not yet concluded that Stalevo increases the risk of heart attack, strokes, or cardiovascular death. The agency said healthcare professionals should regularly evaluate the cardiovascular status of patients who are taking Stalevo, especially if they have a history of cardiovascular disease. Patients should not stop taking Stalevo unless told to do so by their healthcare professional. (more…)
